In our December issue:
FEATURES
Cover Story
Express to Center Stage
William Looney
Pharm Exec profiles Express Scripts’ Chief Medical Officer, Dr. Steve Miller, whose rise to prominence as an articulate critic of drug industry prices symbolizes the growing clout of America’s largest pharmacy benefit manager (PBM). Miller may rank high on today’s list of “pharma’s most feared”—until you pause to consider how closely his background resembles that of so many of his c-suite drug industry peers. |
Innovation Roundtable
Biopharma's Engine Room
It’s time to declare process innovation in drug development and commercialization as a strategic capability—when done well, it can spell all the difference in launching a new product, between life cycle hegemony and that hardly-worth-a-ripple “ho hum.” To shed light on what works and what doesn’t, Pharm Exec convened a prominent global operations strategy consultant, UMT, and four big Pharma practitioners of the art of commercial effectiveness to discuss what makes their days a constant challenge in turning a world of multiplying left-field risks into manageable routines. |
From the Editor
2014: Reading Between the Lines
William Looney
The calendar says it’s wrap-up time, not just for gifts, but for some of the trends that shaped big Pharma—for good or bad—during the past year. A simple way to close the book on 2014 is to draw some insights from our three feature stories this month. Whether by design or circumstance, our efforts reveal the random diversity of threats and opportunities facing the industry today. |
Strategy
The ‘3 S’ Framework for Posy-Deal Growth
Ashkenazy et al
Rebecca Ashkenazy, Alex Chang, Cyndi Green, Ted Miller, and Christine de los Reyes discuss how the '3S' framework — science, synergy, and survival — can build more value in biopharmaceutical dealmaking. |
Marketing
Ready for the Next War?
Faruk Capan
Like many armies, pharmaceutical marketing organizations are usually better equipped to fight the last war rather than the next one. This is plain human nature; after all, today's leaders were yesterday's young rising stars, gaining their formative experiences in that last war. But success, in war and in marketing, usually goes to the side that accepts and acts on the challenges of the new environment more rapidly. |
 |
ALSO IN THIS ISSUE
Pharma Probes Go Global
Jill Wechsler
Foreign governments are enacting anti-fraud legislation as part of broader efforts to crack down on corrupt practices involving pharmaceutical companies and healthcare professionals.
A Forecasting Rx for Pharmacy Benefit Managers
Peter Dillman
The easy wins for pharmacy benefit management (PBM) companies are mostly in the rearview mirror. PBMs face fierce competition, and their core services have essentially become commoditized. To stay ahead of the curve, they should consider using the same forecasting technologies that have brought important savings to the utility and staffing fields. |
| WEBCASTS |
Enhancing Patient Engagement - How to Maximize Nursing and Adherence Solutions
Every day, pharmaceutical companies are challenged to develop cohesive patient support programs that properly engage patients throughout their experience with a product. Discover how you can benefit from recognizing the questions you should be asking and what you can do to keep patients engaged at every point of their health journey and your product lifecycle. Proven customized clinical programs that can help increase adherence will be discussed.
Register Free here
Sponsor: UBC Express Scripts |
Market Access for Orphan Drugs in China
A significant number of patients in China have rare / orphan diseases. As the priority of China's health care reform recently moved to increase the depth of coverage, the number of critical diseases and the percentage of reimbursement by the state continue to increase. In this webinar, we will share with you the opportunities and challenges for orphan drugs to gain access to the patients in China and what a manufacturer could do to prepare for market access in China.
Register Free here
Sponsor: Evidera |
Establishing Processes and Controls to Ensure an Inspection-ready TMF Every Day
The MHRA recently updated its definition of a critical GCP finding to include TMFs that are not readily accessible or incomplete. It is difficult to achieve the right level of control and accessibility without the proper technology. Join PharmaStart's Rebecca Moraris and Veeva's Mike Burton to hear how PharmaStart implemented Veeva Vault eTMF to automate critical processes and provide their partners remote access to the TMF.
Register Free here
Sponsor: Evidera |
